Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilocarpine, Brimonidine, Oxymetazoline Ophthalmic Compound Safety and Efficacy in Patients With Presbyopia

NCT05006911 is registered in ClinicalTrials.gov with Optall Vision as lead sponsor.

NCT NCT05006911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05006911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilocarpine, Brimonidine, Oxymetazoline Ophthalmic Compound Safety and Efficacy in Patients With Presbyopia
Lead sponsor
Optall Vision
Phase
Phase 1
Overall status
Unknown status
Start date
August 14, 2021
Completion date
September 15, 2021
Enrollment
11 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

presbyopia